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INTRODUCTION
A widespread distribution of the 5-HT7 receptor, the latest
serotonin (5-HT) receptor subtype to be identified (1-3) in the
brain (4, 5), underlies its involvement in various brain functions
including circadian rhythmicity (6), sleep and wakefulness
regulation (7) as well as learning and memory (8, 9). Recently
the 5-HT7 receptor has been shown to play an important role in
neuronal plasticity of the mature brain (10).
A large body of experimental evidence suggests a causal link
between alterations in the structure and function of the
hippocampus and the pathophysiology of depression (11, 12).
Exposure of experimental animals to uncontrollable, chronic
stress induces depression-like symptoms including anorexia,
weight loss, anhedonia, fatigue, impaired social interactions and
memory dysfunctions (13). These effects are likely to be related
to modifications in the function of several brain structures,
however, a profound influence of stress on hippocampal synaptic
transmission, plasticity and neuronal excitability appears to
underly the stress-induced deficits in memory tests (14, 15).
While activation of the 5-HT7 receptor exerts procognitive
and antiamnestic effects (16), inactivation and blockade of the 5-
HT7 receptor have been shown to induce an anxiolytic and
antidepressant-like action in animal models of anxiety and
depression, including the elevated plus-maze test in rats and the
forced swim and tail suspension tests in mice (17-20). The
specific 5-HT7 receptor antagonist SB 269970 and
antidepressant drugs exert a synergistic action in the forced
swim test in mice (21, 22). In addition, certain antidepressants
may directly interact with the 5-HT7 receptor (23), which also
suggests that this receptor may constitute a novel target for the
treatment of depression (24, 25). Hence, it has been postulated
that 5-HT7 receptor antagonists might be used for the treatment
of depression, cognitive deficits and anxiety (24-26).
In the hippocampus, axon collaterals of CA3 pyramidal
neurons provide the main excitatory input to CA1 principal
pyramidal cells. The firing of the CA3 pyramidal neurons also
recruits CA1 GABAergic interneurons and generates network
oscillations in the CA1 area via feedforward and feedback
inhibitory interactions (27-29). The activity of the hippocampal
neuronal circuitry remains under the modulatory influence of
5-HT released from fibers originating in the median raphe
nucleus (30-32). Activation of the 5-HT7 receptor, present at
high density in the hippocampus (4, 5) raises the excitability of
neurons of the CA1 and CA3 areas through a decrease in the
amplitude of slow afterhyperpolarization (sAHP) in CA3
pyramidal cells (33, 34) and a reduction of the slow
afterhyperpolarization (sAHP) and frequency adaptation of
action potential firing in CA1 pyramidal neurons (35, 36). The
5-HT7 receptor also enhances the hyperpolarization-activated
cation current Ih in pyramidal cells (37). This receptor appears
to be absent from the hippocampal interneurons (37). We have
shown that administration of the 5-HT7 receptor agonist does
not influence the excitability of CA1 non-accommodating,
fast-spiking GABAergic interneurons (38). We have also
demonstrated that activation of 5-HT7 receptors dose-
dependently increases the frequency of spontaneous inhibitory
postsynaptic currents (sIPSCs) recorded from CA1 pyramidal
neurons (38).
However, in contrast to the effects of 5-HT7 receptor
activation, the mechanisms of the influence of 5-HT7 receptor
antagonists on neuronal activity and synaptic interactions in the
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Effects of the 5-HT7 receptor antagonist SB 269970, administered for 14 days (1.25 mg/kg), were studied in ex vivo
slices of rat hippocampus. To activate the 5-HT7 receptor, 5-carboxamidotryptamine (5-CT, 200 nM) was applied in the
presence of WAY 100635 (2 µM), a 5-HT1A receptor antagonist. In contrast to control preparations, no 5-HT7 receptor-
mediated increase in excitability nor depolarization and an increase in the input resistance of CA1 and CA3 pyramidal
neurons were present in slices prepared from rats treated with SB 269970. The treatment also abolished the stimulatory
effect of 5-HT7 receptor activation on spontaneous excitatory postsynaptic currents recorded from CA1 stratum
radiatum/lacunosum-moleculare interneurons. These data demonstrate that repeated administration of SB 269970
impairs the reactivity of the CA1 hippocampal neuronal network to 5-HT7 receptor activation.
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hippocampus are poorly understood. Using extracellular
recording of bursting network activity in ex vivo hippocampal
slices we have recently shown that repeated administration of SB
269970 to rats results in attenuation of the excitatory effects of
5-HT7 receptors (39). In the present study, we aimed to establish
the effects of treatment with SB 269970 on the reactivity of
electrophysiologically identified major types of hippocampal
neurons to 5-HT7 receptor activation, as well as on the excitatory
input to stratum radiatum/lacunosum-moleculare inhibitory
interneurons.
MATERIALS AND METHODS
Treatment of animals and preparation of hippocampal slices
Experimental procedures were approved by the Animal Care
and Use Committee at the Institute of Pharmacology, Polish
Academy of Sciences, and were carried out in accordance with
the "Principles of Laboratory Animal Care" (NIH publication no.
85-23, revised 1985) and the national law. Male Wistar rats,
weighing approx. 140 g at the beginning of the experiment, were
housed in groups on a controlled light/dark cycle (the light on:
7.00–19.00). The rats had free access to standard food and tap
water. The rats from the experimental group (n=10) received
(2R)-1-[(3-hydroxyphenyl)sulfonyl]-2-[2-(4-methyl-1-
piperidinyl)ethyl]pyrrolidine hydrochloride (SB 269970; 1.25
mg/kg i.p., dissolved in 0.9% NaCl, volume: 1 ml/kg) once daily
for 14 days. The animals from the control group (n=10) received
0.9% NaCl only.
Two days after the last injection the rats were anesthetized
with isoflurane and were then decapitated. Their brains were
quickly removed and placed in an ice-cold (0°C) artificial
cerebrospinal fluid (ACSF), composed of (in mM) NaCl (130),
KCl (5), CaCl2 (2.5), MgSO4 (1.3), KH2PO4 (1.25), NaHCO3
(26) and D-glucose (10) and bubbled with a mixture of 95% O2
- 5% CO2. Transverse hippocampal slices (thickness: 420 µm)
were cut using a vibrating microtome (Leica VT1000) and were
then stored submerged in ACSF at 32 ± 0.5°C.
Whole-cell recording
After at least 3 hours of preincubation, a slice was placed in
the recording chamber superfused at 2.5 ml/min with warm (32 ±
0.5°C), modified ACSF composed of (in mM) NaCl (132), KCl
(2), KH2PO4 (1.25), NaHCO3 (26), MgSO4 (1.3), CaCl2 (2.5) and
D-glucose (10), bubbled with 95% O2 - 5% CO2. Neurons were
visualized using the Zeiss Axioskop 2 upright microscope
(Nomarski optics), a 40 × water immersion lens and an infrared
camera (35). Patch pipettes were pulled from borosilicate glass
capillaries (Clark Electromedical Instruments) using the Sutter
Instrument P87 puller and were then filled with a solution
containing (in mM) 130 K-gluconate, 5 NaCl, 0.3 CaCl2, 2
MgCl2, 10 HEPES, 5 Na2-ATP, 0.4 Na-GTP, and 1 EGTA
(osmolarity: 290 mOsm, pH = 7.2; 40). The pipettes had an open
tip resistance of approx. 6 MΩ.
Signals were recorded from CA1 and CA3 pyramidal
neurons and CA1 stratum radiatum/lacunosum-moleculare
interneurons using the MultiClamp 700B amplifier and were
digitized at 20 kHz using the Digidata 1400 interface
(Molecular Devices, USA). Neurons were distinguished on the
basis of the morphology of the cell body and the responses to a
series of hyper- and depolarizing current pulses (38).
Spontaneous excitatory postsynaptic currents (sEPSCs) were
recorded for 8 min as inward currents at a holding potential of
–76 mV, as described previously (40). Individual events were
detected off-line and analyzed using the Mini Analysis software
(Synaptosoft, USA). Data were accepted for analysis when the
access resistance ranged between 15-18 MΩ and was stable
(<25% change) during the recording.
To activate 5-HT7 receptors, 200 nM 5-carboxamidotry-
ptamine (5-CT, Tocris), an agonist of 5-HT1A and 5-HT7 receptors,
was added to the modified ACSF for 15 min in the presence of 2
µM N-[2-[4-(2-methoxyphenyl)-1piperazinyl]ethyl]-N-2-pyridi-
nylcyclohexanecarboxamide (WAY 100635, Sigma Aldrich), a
selective 5-HT1A receptor antagonist, which was introduced at least
20 min earlier (35, 41).
Statistical analysis
Statistical analysis was carried out using unpaired or paired
Student's t tests. The data are presented as the mean ± S.E.M.
RESULTS
Repeated administration of SB 269970 abolishes the effects
of 5-HT7 receptor activation in pyramidal neurons
To test the effects of 5-HT7 receptor activation on the intrinsic
excitability of pyramidal cells, a series of depolarizing current
pulses (500 ms) were applied before and again after addition of 5-
CT (an agonist of 5-HT7 and 5-HT1A receptors; 42) to the ACSF
(in the presence of WAY 100635 to block 5-HT1Areceptors). In the
slices obtained from control animals, activation of the 5-HT7
receptor increased the number of spikes generated by the injected
current in both CA1 (Fig. 1A1-4) and CA3 (Fig. 2A1-4) pyramidal
neurons. That effect was most prominent at low values of current
intensity, while at its high values the number of spikes generated
for a given current before and after addition of 5-CT was similar.
The 5-HT7 receptor-mediated change in the intrinsic excitability
(gain)- of pyramidal neurons was more substantial in CA3
compared to CA1 cells (58.3 ± 5.9% vs. 32.6 ± 3.6%, respectively;
the mean ±S.E.M., P<0.05, t-test). However, in the slices prepared
from rats injected with SB 269970, the application of 5-CT did not
result in an increase in excitability (Figs. 1B1-4, and 2B1-4). In
control preparations, activation of the 5-HT7 receptor resulted in a
small depolarization and an increase in the input resistance of CA1
and CA3 pyramidal cells as well (Table 1) . Those effects were
absent from neurons obtained from SB 269970-treated rats.
Treatment with SB 269970 did not affect the basic membrane
properties of CA1 and CA3 pyramidal cells (Table 1).
Repeated administration of SB 269970 abolishes the effect of
5-HT7 receptor activation on sEPSCs recorded from
GABAergic interneurons
Spontaneous EPSCs were recorded from CA1 stratum
radiatum/lacunosum-moleculare fast-spiking interneurons (Fig.
3). Basic membrane properties of these cells are summarized in
Table 2. The mean frequency of sEPSCs recorded in the standard
ACSF (termed: baseline frequency) was not significantly
different in the interneurons obtained from control rats compared
to those from rats receiving SB 269970 (Table 2). 5-CT
application (in the presence of WAY 100635) increased the mean
frequency of sEPSCs in control preparations (Figs. 3B1 and C,
Table 2). However, in slices prepared from rats receiving SB
269970, application of 5-CT did not result in an increase in the
mean frequency of sEPSCs (Figs. 3B2 and C, Table 2).
Activation of 5-HT7 receptors remained without effect on the
mean amplitude of sEPSCs in both control slices and slices
prepared from rats receiving SB 269970 (Fig. 3D, Table 2).
Activation of 5-HT7 receptors affected the excitability of
recorded interneurons in neither control slices nor slices
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Fig. 1. The lack of effect of 5-HT7 receptor activation on the excitability of CA1 pyramidal neurons after treatment with SB 269970.
(A1) A typical example of the response of a pyramidal cell obtained from a control rat to a depolarizing current pulse (250 pA) under
baseline conditions (to the left), and after addition of 5-CT to ACSF (to the right). (A2) An example of a response at a higher stimulation
intensity (500 pA) before and after addition of 5-CT. (A3) The injected current vs. spiking rate relationship in a representative control
cell before (baseline recording; open circles) and after application of 5-CT (filled circles). Solid lines represent linear fits to the
experimental data. (A4) The mean (± S.E.M.) slope (i.e. gain) of the current vs. spiking rate relationship under baseline conditions (open
bar) and after application of 5-CT (filled bar; n=19 cells; * P<0.05, paired t - test). (B1 and B2) Typical examples of responses to
depolarizing current pulses (250 and 500 pA) under baseline conditions and after addition of 5-CT to ACSF in a slice obtained from a
rat treated with SB 269970. (B3) The injected current vs. spiking rate relationship in a representative cell from a treated rat before (open
circles) and after application of 5-CT (black circles). Continuous lines represent linear fits to the experimental data. (B4) Mean (±
S.E.M.) slope of the current vs. spiking rate relationship under baseline conditions (open bar) and after application of 5-CT in 19 cells
obtained from SB 269970-treated rats (filled bar). The difference is not statistically significant.
prepared from rats receiving SB 269970, as the mean slope
(gain) of the current versus the spiking rate relationship in
interneurons originating from treated and control animals was
similar (Fig. 3E).
DISCUSSION
The results of the present study indicate that treatment of rats
with the specific 5-HT7 receptor antagonist SB 269970 abolishes
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Fig. 2. The lack of effect of 5-HT7 receptor activation on the excitability of CA3 pyramidal neurons after treatment with SB 269970.
(A1-3) Examples of the responses of a control cell. (B1-3) Examples of responses of a cell obtained after treatment with SB 269970.
(A4 and B4) The mean (± S.E.M.) slope of the current vs. spiking rate relationship of pyramidal cells in baseline conditions (open
bars) and after application of 5-CT (filled bars) in control slices (A4, n=7) and slices obtained after treatment with SB 269970 (B4,
n=8). All labels as in Fig. 1.
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Fig. 3. The influence of 5-HT7 receptor activation on spontaneous EPSCs recorded from fast-spiking interneurons. (A) An example of
the responses of a representative control interneuron to a depolarizing current pulse. (B1-2) Examples of raw recordings of sEPSCs
before (baseline, left trace) and after (right trace) application of 5-CT from interneurons in a control slice (B1) and in a slice prepared
from a rat receiving injections of SB 269970 (B2). (C) Application of 5-CT increases the mean frequency (± S.E.M.) of sEPSCs in
control interneurons (open bar, n=18) but not in cells obtained from rats receiving injections of SB 269970 (filled bar, n=15). * P<0.05,
t - test). (D) Application of 5-CT influences the amplitude of sEPSCs in neither control nor SB 269970-treated preparations; the means
± S.E.M. (E) The injected current vs. spiking rate relationship (the mean ± S.E.M.) in control cells (open circles) and interneurons
originating from rats receiving SB 269970 (filled circles).
the effects of 5-HT7 receptor activation on the intrinsic
excitability of hippocampal pyramidal neurons. It is noteworthy
that some studies that used expression systems allowing detection
of the constitutive activity of the 5-HT7 receptor described SB
269970 as an inverse agonist (e.g. 43). The constitutive activity
of the 5-HT7 receptor appears to be regulated by palmitoylation
of the C-terminal domain of the receptor protein (44).
In slices obtained from untreated rats, addition of 200 nM 5-
CT to the ACSF containing 2 µM WAY 100636 resulted in an
increased number of spikes generated in CA1 and CA3
pyramidal neurons by lower intensity depolarizing current
pulses, a change in the resting membrane potential and an
increase in the input resistance. These observations are
consistent with some earlier studies which demonstrated that
activation of the 5-HT7 receptor decreased K+ conductances and
increased the Ih current, thus raising the excitability of
hippocampal pyramidal cells (33, 35, 37). Interestingly, the
effect of 5-HT7 receptor activation was stronger in CA3
compared to CA1 pyramidal cells which potentially may have
resulted from a greater 5-HT7 receptor density in the CA3 area
(4, 45). Such effects of 5-HT7 receptor activation were absent
from slices prepared from rats treated with SB 269970. We have
recently demonstrated that treatment of rats with SB 269970
following a regime identical to that used in the present study
results in attenuation, but not abolishment, of the excitatory
effects of 5-HT7 receptor activation on extracellularly-recorded,
spontaneous network activity which can be induced in
hippocampal slices by incubation in the Mg2+-free ACSF (39).
Moreover, in slices prepared from SB 269970-treated rats, the
basal frequency of spontaneous bursts has been found to be
lower than in control preparations (39). In the present study, no
significant difference in the frequency of spontaneous EPSCs
was observed in interneurons obtained from SB 269970-treated
and control rats. It is noteworthy that in the present study the
recordings were performed under conditions that effectively
prevented the occurrence of NMDA receptor-mediated
postsynaptic currents. Thus, the differences in the experimental
conditions during recording are likely to account for such an
apparent discrepancy.
We previously demonstrated that SB 269970, administered
for 14 days, induced a decrease in the maximum density (Bmax)
of 5-HT7 receptors in rat hippocampus without changing their
mean affinity for [3H]-SB 269970 (39). Moreover, treatment
with SB 269970 resulted in a decrease in the expression level of
mRNAs for Gαs and Gα12 proteins (39), which are known to be
activated by the 5-HT7 receptor and to mediate its actions (46).
Hence, the present findings are consistent with the treatment-
induced reduction in the amount of available 5-HT7 receptors
and the impairment of 5-HT7 receptor-activated intracellular
signaling cascades in the cytoplasm of pyramidal neurons.
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control SB 269970 
baseline in 5-CT baseline in 5-CT 
Resting membrane 
potential Vm (mV) 
–64.1 ± 0.4 –62.9 ± 0.5* –63.7 ± 0.4 –63.3 ± 0.5 
Input resistance  
Rm (M) 
68.4 ± 4.5 83.1 ± 6.8*** 58.2 ± 3.4 60.7 ± 6.0 
CA1 
n 19 19 
Resting membrane 
potential Vm (mV) 
–63.2 ± 0.4 –60.4 ± 0.2** –63.8 ± 0.8 –63.3 ± 0.9 
Input resistance  
Rm (M) 
77.6 ± 13.8 99.5 ± 12.0*** 81.7 ± 20.0 84.4 ± 18.7 
CA3 
n 7 8 
The data are presented as the mean ± S.E.M. Baseline, the data obtained before addition of 5-CT to the ACSF; in 5-CT, the data
obtained after addition of 5-CT to the ACSF. * P<0.05, ** P<0.01, *** P<0.001; paired t - test. The differences between baseline values
in the control and the SB 269970 group are not significant.
Table 1. Basic membrane properties of CA1 and CA3 pyramidal neurons and the effects of 5-HT7 receptor activation in slices obtained
from control rats and animals treated with SB 269970.
control SB 269970 
Resting membrane potential Vm (mV) –69.2 ± 3.1 –70.3 ± 4.4 
Input resistance Rm (M) 187.8 ± 34.6 192.1 ± 33.9
baseline 2.36 ± 0.5 1.67 ± 0.4 
Mean frequency of sEPSCs (Hz) 
5-CT 2.98 ± 0.5** 1.72 ± 0.5 
baseline 11.60 ± 1.2 13.05 ± 1.4 
Mean amplitude of sEPSCs (pA) 5-CT 11.71 ± 1.2 12.90 ± 1.4 
n 18 15 
The data are presented as the mean ± S.E.M. ** P≤0.01 (baseline vs. 5-CT; paired t - test).
Table 2. Basic membrane properties and the effects of 5-HT7 receptor activation on sEPSCs recorded from fast-spiking interneurons
in slices obtained from control rats and animals treated with SB 269970.
The present data confirm our earlier findings that application of
5-CT in the presence of WAY 100635 increased the frequency of
sEPSCs recorded from fast-spiking stratum radiatum/lacunosum-
moleculare interneurons, but did not influence the excitability of
those cells (38). The present results also demonstrate that the 5-HT7
receptor-mediated increase in the frequency of sEPSCs recorded
from fast-spiking interneurons does not occur in slices obtained
from SB 269970-treated animals. This observation is consistent
with the fact that CA1 interneurons receive excitatory connections
from CA1 and CA3 pyramidal neurons (47). These cells lose the
reactivity to 5-HT7 receptor activation after treatment with SB
269970 (present study). Since GABAergic interneurons modulate
the activity of pyramidal neurons, treatment with SB 269970
should result in a lack of 5-HT7 receptor-mediated enhancement of
the GABAergic input to CA1 pyramidal cells, under normal
conditions being an indirect consequence of the increased
excitatory input to GABAergic interneurons due to activation of 5-
HT7 receptors located on glutamatergic cells (35, 38).
Experimental evidence supports the involvement of
abnormalities in the GABAergic inhibition in the development
of neuropsychiatric diseases such as schizophrenia, autism and
depression (48-52). Some data also suggest that alterations in the
adequate balance and correct integration of the GABAergic
transmission originating from diverse interneuron sources may
lead to the development of depression (53, 54). There also exists
some experimental evidence that antidepressant drugs can
modulate GABAergic transmission in the hippocampus through
modifications of the monoaminergic tone (55, 56) or a direct
modulation of GABAA receptors (57) or, finally, through
changes in GABA release, not involving monoaminergic
transmission (53, 58).
Treatment of rats with antidepressant drugs attenuates the
excitatory effects of activation of the 5-HT7 receptor in the
hippocampus (41). Similar effects are induced by treatment with
the 5-HT7 receptor antagonist SB 269970 (39, present study).
Summing up, the above data support the hypothesis that the
phenomenon of the functional desensitization of 5-HT7 receptor
system, which leads to alterations in GABAergic transmission,
may represent one of the mechanisms of action of antidepressants
(24, 59) and the antidepressant action of 5-HT7 antagonists.
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